At a glance
- Originator Chugai Pharmaceutical
- Class Dibenzazepines; Nootropics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cognition disorders
Most Recent Events
- 10 Jul 1998 Discontinued-II for Cognition disorders in Japan (Unknown route)
- 20 Jan 1997 No-Development-Reported for Cognition disorders in Japan (Unknown route)